Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial

Despite the benefits of pioglitazone in the treatment of non-alcoholic fatty liver disease (NAFLD), many treated patients continue to experience disease progression. We aimed to investigate the additive effect of ipragliflozin on NAFLD in patients with type 2 diabetes treated with metformin and piog...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Eugene, Lee, Yong-ho, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019437/
https://www.ncbi.nlm.nih.gov/pubmed/31963648
http://dx.doi.org/10.3390/jcm9010259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019437/
https://www.ncbi.nlm.nih.gov/pubmed/31963648
http://dx.doi.org/10.3390/jcm9010259

Ejemplares similares